Background {#Sec1}
==========

Increasingly in scientific literature, DA-HAIs are considered to be among the principal threat to patient safety in the ICU and are among the main causes of patient morbidity and mortality \[[@CR1],[@CR2]\].

The effectiveness of implementing an integrated infection control programme focused on device-associated healthcare-acquired infection (DA-HAI) surveillance was demonstrated in the many studies conducted in the U.S., whose results reported not only that the incidence of DA-HAI can be reduced by as much as 30%, but that a related reduction in healthcare costs was also feasible \[[@CR3]\]. In the same way, it is fundamental to address the burden of antimicrobial-resistant infections that the pathogens and the susceptibility to antimicrobials of DA-HAI-associated pathogens be reported, so that informed decisions can be made to effectively prevent transmission of resistant strains and their determinants, such as strains with phenotypes with very few available treatments with chances of success \[[@CR4]\].

For more than 30 years, the U.S. the Centers for Disease Control and Prevention (CDC)'s National Healthcare Safety Network (NHSN) \[[@CR5]\] has provided benchmarking U.S. ICU data on DA-HAIs, which have proven invaluable for researchers \[[@CR5]\], and served as an inspiration to the INICC \[[@CR6]\]. The INICC is an international non-profit, open, multi-centre, collaborative healthcare-associated infection control programme with a surveillance system based on that of the CDC's NHSN \[[@CR5]\]. Founded in Argentina in 1998, INICC is the first multinational research network established to measure, control and reduce DA-HAI in ICUs and surgical site infections (SSIs) hospital wide through the analysis of data collected on a voluntary basis by a pool of hospitals worldwide \[[@CR6],[@CR7]\]. The INICC has the following goals: To create a dynamic global network of hospitals worldwide and conduct surveillance of DA-HAIs and SSIs using standardized definitions and established methodologies, to promote the implementation of evidence-based infection control practices, and to carry out applied infection control research; to provide training and surveillance tools to individual hospitals which can allow them to conduct outcome and process surveillance of DA-HAIs and SSIs, to measure their consequences, and assess the impact of infection control practices; to improve the safety and quality of healthcare world-wide through the implementation of systematized programmes to reduce rates of DA-HAIs and SSIs, their associated mortality, excess lengths of stay (LOS), excess costs, antibiotic usage, and bacterial resistance \[[@CR8]\].

This report is a summary of data on DA-HAIs collected in 63 intensive care units (ICUs) in 29 Turkish hospitals from 19 cities participating in the International Nosocomial Infection Control Consortium (INICC) between August 2003 and October 2012 \[[@CR6],[@CR7]\].

Methods {#Sec2}
=======

Setting and study design {#Sec3}
------------------------

This prospective cohort surveillance study was conducted in 63 adult, paediatric ICUs and neonatal ICUs (NICUs) from 29 hospitals in 19 cities. Hospitals were stratified by bed numbers (\<200, 201--500, 501--1000, and \>1000).

The ICUs were stratified according to the patient features: adult, paediatric or NICUs. The types of ICU participating in this study were the following: Cardiothoracic, Medical, Medical Cardiac, Medical/Surgical, Neurologic, Neurosurgical, Neonatal, Paediatric, Respiratory and Surgical.

According to the level of complexity of care, the NICUs included the following levels:Level IIIA: It provides care to neonatal patients born at ≥28 weeks, who weigh ≥1,000 grams. The provide mechanical ventilation and minor surgical procedures, such as umbilical vessel catheterization.Level IIIB: It provides care to neonatal patients born at any viable gestational age. Mechanical ventilation and high-frequency mechanical ventilation are provided. There are paediatric surgical centres on site or nearby to complete major surgical procedures.Level IIIC: It provides the highest level of NICU care. In addition to the capabilities of Level IIIA and B, it provides extra corporeal membrane oxygenation and complicated surgical procedures requiring cardiopulmonary bypass are performed as well.

INICC methodology {#Sec4}
-----------------

The INICC is focused on the surveillance and prevention of DA-HAI in adult, paediatric ICUs and neonatal ICUs (NICUs), and of SSIs in surgical procedures hospital wide \[[@CR6],[@CR7]\]. The INICC has both outcome surveillance and process surveillance components. The modules of the components may be used singly or simultaneously, but, once selected; they must be used for a minimum of 1 calendar month. All DA-HAIs and SSIs of the Outcome Surveillance Component are categorized using standard NHSN definitions that include laboratory tests, radiology tests, and clinical criteria \[[@CR9]\]. Laboratory-confirmed BSIs are recorded and reported \[[@CR9]\].

The Outcome Surveillance Component related to DA-HAI classifies surveillance data into specific module protocols that include excess LOS, evaluation of DA-HAI costs, crude excess length of stay, crude excess mortality, microbiological profile, bacterial resistance, and antimicrobial-use data. Data on DA-HAI costs were not included in this report. Data from the INICC Process Surveillance Module, which includes monitoring of hand hygiene, vascular catheter care, urinary catheter care, and mechanical ventilator care compliance, were not included in this report.

Training, validation, and reporting {#Sec5}
-----------------------------------

The INICC Chairman trained the principal and secondary investigators at hospitals. Investigators were also provided with a manual and training tool that described in detail how to perform surveillance and complete surveillance forms. In addition, investigators had continuous e-mail and telephone access to a support team at the INICC Central Office in Buenos Aires, Argentina.

Each month, participating hospitals submitted the completed surveillance forms to the INICC Central Office, where the validity of each case was checked and the recorded signs and symptoms of infection and the results of laboratory studies, radiographic studies, and cultures were scrutinized to assure that the U.S. NHSN criteria for DA-HAI had been met. The forms used for surveillance of each ICU patient permit both internal and external validation, because they include every clinical and microbiological criterion for each type of DA-HAI \[[@CR6],[@CR8]\]. Therefore, the investigator who reviewed the data forms filled in at the participating hospital verified that adequate criteria for infection had been fulfilled in each case; and the original patient data form was further validated at the INICC Central Office before data on the reported infection are entered into the INICC's database.

Data collection {#Sec6}
---------------

Using standardized INICC detailed forms and following the INICC protocol and U.S. NHSN's definitions \[[@CR9]\], infection control professionals (ICPs), trained and with previous experience conducting surveillance of DA-HAIs, collected data on central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs) and ventilator-associated pneumonias (VAPs) in the ICUs.

In the NICUs, ICPs collected data on CLABSIs and umbilical catheter-associated primary bloodstream infections or VAPs for each of 5 birth-weight categories (\<750 g, 750--1000 g, 1001 -- 1500 g, 1501 -- 2500 g, \>2500 g), Corresponding denominator data, patient-days and specific device-days were also collected by the ICPs.

Detailed and aggregated data were used to calculate DA-HAI rates per 1000 device-days. Only prospective data using INICC patient detailed forms were used to calculate mortality and LOS.

In accordance with the INICC's Charter, the identity of all INICC hospitals and cities is kept confidential.

Data analysis {#Sec7}
-------------

Data for adult combined medical/surgical ICUs were not stratified by type or size of hospital. Data for NICUs were stratified by weight categories: central line-days, urinary catheter-days, or ventilator days.

Device-days consisted of the total number of central line (CL)-days, urinary catheter (UC)-days, or mechanical ventilator (MV)-days. For NICUs, device-days consisted of the total number of CL-days, UC-days, and MV-days.

Crude excess mortality of DA-HAI equals crude mortality of ICU patients with DA-HAI minus crude mortality of patients without DA-HAI.

Crude excess LOS of DA-HAI equals crude LOS of ICU patients with DA-HAI minus crude LOS of patients without DA-HAI.

Comparisons of the percentile distribution were made if there were at least 7 locations contributing to the strata.

EpiInfo® version 6.04b (CDC, Atlanta, GA) and SPSS 16.0 (SPSS Inc. an IBM company, Chicago, Illinois) were used to conduct data analysis. Relative risk (RR) ratios, 95% confidence intervals (CIs) and P-values were determined for primary and secondary outcomes.

Results {#Sec8}
=======

The characteristics of 63 ICUs from 29 hospitals in 19 cities from Turkey currently participating in INICC that contributed data for this report are shown in Table [1](#Tab1){ref-type="table"}. The length of hospital's participation in the INICC Programme is as follows: mean length of participation ± SD, 28.7 ± 25.7 months, range 3 to 85 months.Table 1**Characteristics of the participating intensive care units\<200 beds hospitals201-500 bed hospitals501-1000 bed hospitals\>1000 bed hospitalsOverall**No. of hospitals3 (10%)8 (28%)10 (34%)8 (28%)29 (100%)No. of ICUs4 (6%)20 (32%)29 (46%)10 (16%)63 (100%)Medical Cardiac1 (25%)2 (50%)1 (25%)0 (0%)4 (100%)Cardiothoracic0 (0%)1 (33%)1 (33%)1 (33%)3 (100%)Medical0 (0%)4 (44%)3 (33%)2 (22%)9 (100%)Medical/Surgical1 (5%)5 (26%)9 (47%)4 (21%)19 (100%)Neonatal1 (17%)2 (33%)2 (33%)1 (17%)6 (100%)Neurologic0 (0%)0 (0%)2 (100%)0 (0%)2 (100%)Neurosurgical0 (0%)1 (33%)2 (67%)0 (0%)3 (100%)Paediatric1 (14%)1 (14%)4 (57%)1 (14%)7 (100%)Respiratory0 (0%)1 (50%)1 (50%)0 (0%)2 (100%)Surgical0 (0%)3 (38%)4 (50%)1 (13%)8 (100%)ICU, intensive care unit.

For the Outcome Surveillance Component, DA-HAI rates, device utilization (DU) ratios, crude excess mortality by specific type of DA-HAI, microorganism profile and bacterial resistance from August 2003 through October 2012 are summarized (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}, [11](#Tab11){ref-type="table"}, [12](#Tab12){ref-type="table"} and [13](#Tab13){ref-type="table"}).Table 2**Pooled means of central line-associated bloodstream infection rates, urinary catheter-associated urinary tract infection rates, and ventilator-associated pneumonia by hospital sizeHospital size, beds, nICUs, nPatients, nBed days, nCL days, nCLABSI, nCLABSI rate (95% CI)MV days, nVAP, nVAP, Rate (95% CI)UC days, nCAUTI, nCAUTI, rate (95% CI)**\<200371314 7069,459414.3 (31 -- 5.9)7,536405.3 (3.8 - 7.2)10 621434.0 (2.9 - 5.5)201-5001823 896167 05888 9173824.3 (3.9 -- 4.7)84 714219325.9 (24.8 - 26.9)142 9656524.6 (4.2 - 4.9)501-10002761 350382 283189 7281,93910.2 (9.8 -- 10.7)142 735315222.1 (21.3 - 22.8)314 84729579.4 (9.0 - 9.7)\>100095,1094,91431 43232910.5 (9.4 -- 11.7)37 31043111.6 (10.4 - 12.7)42 1061804.3 (3.7 - 4.9)**Pooled**5791 068613,191319 5362,6918.4 (8.1 -- 8.7)272 2955,81621.4 (20.8 - 21.9)510 5393,8327.5 (7.3 - 7.7)Adult and Paediatric Patients. DA module, 2003-2012ICU, intensive care units; CL, central line; CLABSI, central line-associated bloodstream infection; CI, confidence interval; MV, mechanical ventilator; VAP, ventilator-associated pneumonia; UC, urinary catheter; CAUTI, catheter-associated urinary tract infection.Table 3**Pooled means of central line-associated bloodstream infection rates, and ventilator-associated pneumonia by hospital sizeHospital size, beds, nICUs, nPatients, nBed days, nCL daysCLABSI, NCLABSI rate (95% CI)MV days, nVAP, nVAP, rate (95% CI)**\<20014404,45726929107.8 (72.2 -- 154.8)2731140.3 (20.2 - 70.9)201-50023834,834170663.5 (1.3 -- 7.7)1,2061915.8 (9.0 - 24.5)501-100021,44216 82622065123.1 (17.2 -- 30.4)3,046289.2 (6.1 - 13.2)\>100011,1658,00810492422.9 (14.7 -- 34.0)9852929.4 (19.8 - 42.0)**Pooled**63,43034 1255,23011021.0 (17.3 -- 25.3)5,5108715.8 (12.6 - 19.5)Neonatal Patients. DA module, 2003--2012.ICU, intensive care units; CL, central line; CLABSI, central line-associated bloodstream infection; CI, confidence interval; MV, mechanical ventilator; VAP, ventilator-associated pneumonia.Table 4**Pooled means and key percentiles of the distribution of central line-associated bloodstream infection rates, by type of location, adult and paediatric patientsType of ICUICU, nPatientsBed daysCL daysCLABSI, nCLABSI rate95% CIPercentiles\*1025507590**Medical Cardiac45,38022 74310 838464.23.1 -- 5.7\-\-\-\--Cardiothoracic37,80021 79615 165221.50.9 -- 2.2\-\-\-\--Medical921 854170 04279 3435256.66.1 -- 7.22.53.87.311.1-Medical/Surgical1919 410175 470113 5979698.58.0 -- 9.10.04.211.715.118.3Neurologic23,78430 9668,6909110.58.4 -- 12.9\-\-\-\--Neurosurgical35,69139 71918 5791035.54.5 -- 6.7\-\-\-\--Paediatric74,23532 14812 8801229.57.9 -- 11.30.02.710.613.6-Respiratory21,75414 0544,9505911.99.1 -- 15.4\-\-\-\--Surgical821 160106 25355 49475413.612.6 -- 14.61.63.59.817.2-**Pooled**5791 068613 191319 5362,6918.48.1 -- 8.71.03.98.613.818.2DA module, 2003--2012.ICU, intensive care unit; CL, central line; CLABSI, central line-associated bloodstream infection; CI, confidence interval.\*Comparisons of the percentile distribution were made if there were at least 7 locations contributing to the strata.Table 5**Pooled means of the distribution of central line-associated bloodstream infection rates for level III NICUs, stratified by birth-weight categoryBirth-weight categoryICU, nPatientsBed daysCL daysCLABSI, nCLABSI rate95% CI**\<750 grams498617250936.016.5 -- 68.3751-1000 grams62974,1971,6393018.312.3 -- 26.11001-1500 grams664910 6521,4654832.824.2 -- 43.41501-2500 grams61,20210 9981,02487.83.4 -- 15.4\>2500 grams61,1847,6618521517.69.9 -- 29.0**Pooled**63,43034 1255,23011021.017.3 -- 25.3DA module, 2003--2012.ICU, intensive care unit; CL, central line; CLABSI, central line-associated bloodstream infection; CI, confidence interval.Table 6**Pooled means and key percentiles of the distribution of ventilator-associated pneumonia rates, by type of location, adult and paediatric patientsType of ICUICUs, nPatientsBed daysMV daysVAP, nVAP rate95% CIPercentiles\*1025507590**Medical Cardiac45, 38022 7435,8205810.07.6 --12.9\-\-\-\--Cardiothoracic37,80021 7969,99312312.310.2 -- 14.7\-\-\-\--Medical921 854170 04282 378183622.321.3 -- 23.38.312.622.132.7-Medical/Surgical1919 410175 47095 021211622.321.3 -- 23.29.612.816.528.642.9Neurologic23,78430 9667,40517623.820.4 -- 27.6\-\-\-\--Neurosurgical35,69139 7198,85925228.425.0 -- 32.2\-\-\-\--Paediatric74,23532 14817 06820011.710.2 -- 13.52.96.210.614.1-Respiratory21,75414 0548,15620425.021.7 -- 28.7\-\-\-\--Surgical821 160106 25337 59585122.621.1 -- 24.212.618.521.926.7-**Pooled**5791 068613 191272 2955,81621.420.8 -- 21.97.211.220.527.735.4DA module, 2003--2012.ICU, intensive care unit; MV, mechanical ventilator; VAP, ventilator-associated pneumonia; CI, confidence interval.\*Comparisons of the percentile distribution were made if there were at least 7 locations contributing to the strata.Table 7**Pooled means of the distribution of ventilator-associated pneumonia rates for level III NICUs, stratified by Birth-weight categoryBirth-weight categoryICUs, nPatientsBed daysMV daysVAP, nVAP rate95% CI**\<750 grams498617236416.94.6 -- 43.4751-1000 grams629741971,4072517.811.5 -- 26.21001-1500 grams664910 6521,3071914.58.8 -- 22.71501-2500 grams61,20210 9981,3181914.48.7 -- 22.5\>2500 grams61,1847,6611,2422016.19.8 -- 24.9**Pooled**63,43034 1255,5108715.812.6 -- 19.5DA module, 2003-2012.ICU, intensive care unit; MV, mechanical ventilator; VAP, ventilator-associated pneumonia; CI, confidence interval.Table 8**Pooled means and key percentiles of the distribution of urinary catheter-associated urinary tract infection rates, by type of location, adult and paediatric patientsType of ICUICU, nPatientsBed daysUC daysCAUTI, nCAUTI, rate95% CIPercentiles\*1025507590**Medical Cardiac45,38022 74314 907493.32.4 - 4.3\-\-\-\--Cardiothoracic37,80021 79618 744683.62.8 - 4.6\-\-\-\--Medical921 854170 042143 4557395.24.8 - 5.52.12.84.08.9-Medical/Surgical1919 410175 470154 4221,2207.97.5 - 8.42.12.85.89.113.7Neurologic23,78430 96629 85659620.018.4 - 21.6\-\-\-\--Neurosurgical35,69139 71936 6883479.58.5 - 10.5\-\-\-\--Paediatric74,23532 14810 981736.65.2 - 8.41.11.83.910.7-Respiratory21,75414 05412 833503.92.9 - 5.1\-\-\-\--Surgical821 160106 25388 6536907.87.2 - 8.41.72.85.58.9-**Pooled**5791 068613 191510 5393,8327.57.3 - 7.71.72.64.98.514.2DA module, 2003--2012.ICU, intensive care unit; UC, urinary catheter; CAUTI, catheter-associated urinary tract infection; CI, confidence interval.\*Comparisons of the percentile distribution were made if there were at least 7 locations contributing to the strata.Table 9**Pooled means of the distribution of central line utilization ratios, urinary catheter utilization ratios, and ventilator utilization ratios, by type of location, adult and paediatric patientsICU typeICU, nBed daysCL daysDUR, central line (95% CI)MV daysDUR, MV (95% CI)UC daysDUR, UC (95% CI)**Medical Cardiac422 74310 8380.48 (0.47 -- 0.48)5,8200.26 (0.25 -- 0.26)14 9070.66 (0.65 -- 0.66)Cardiothoracic321 79615 1650.70 (0.69 -- 0.70)9,9930.46 (0.45 -- 0.47)18 7440.86 (0.86 -- 0.86)Medical9170 04279 3430.47 (0.46 -- 0.47)82 3780.48 (0.48 -- 0.49)143 4550.84 (0.84 -- 0.85)Medical/Surgical19175 470113 5970.65 (0.65 -- 0.65)95 0210.54 (0.54 -- 0.54)154 4220.88 (0.88 -- 0.88)Neurologic230 9668,6900.28 (0.28 -- 0.29)7,4050.24 (0.23 -- 0.24)29 8560.96 (0.96 -- 0.97)Neurosurgical339 71918 5790.47 (0.46 -- 0.47)8,8590.22 (0.22 -- 0.23)36 6880.92 (0.92 -- 0.93)Paediatric732 14812 8800.40 (0.40 -- 0.41)17 0680.53 (0.53 -- 0.54)10 9810.34 (0.34 -- 0.35)Respiratory214 0544,9500.35 (0.34 -- 0.36)8,1560.58 (0.57 -- 0.59)12 8330.91 (0.91 -- 0.92)Surgical8106 25355 4940.52 (0.52 -- 0.53)37 5950.35 (0.35 -- 0.36)88 6530.83 (0.83 -- 0.84)**Pooled**57613 191319 5360.52 (0.52 -- 0.52)272 2950.44 (0.44 -- 0.45)510 5390.83 (0.83 -- 0.83)DA module, 2003--2012.ICU, intensive care unit; CL, central line; MV, mechanical ventilator; UC, urinary catheter; DUR, device use ratio; CI, confidence interval.Table 10**Pooled means of the distribution of central line utilization ratios and ventilator utilization ratios, by type of location, for level III NICUsBirth-weight categoryICU, nBed daysCL daysDUR, central line (95% CI)MV daysDUR, MV (95% CI)**\<750 grams46172500.41 (0.37 -- 0.45)2360.38 (0.34 -- 0.42)751-1000 grams6419716390.39 (0.38 -- 0.41)14070.34 (0.32 -- 0.35)1001-1500 grams61065214650.14 (0.13 -- 0.14)13070.12 (0.12 -- 0.13)1501-2500 grams61099810240.09 (0.09 -- 0.10)13180.12 (0.11 -- 0.13)\>2500 grams676618520.11 (0.10 -- 0.12)12420.16 (0.15 -- 0.17)\<750 grams63412552300.15 (0.15 -- 0.16)55100.16 (0.16 -- 0.17)DA module, 2003--2012.ICU, intensive care unit; CL, central line, MV, mechanical ventilator; DUR, device use ratio; CI, confidence interval.Table 11**Pooled means of the distribution of crude mortality and crude excess mortality of adult and paediatric intensive care unit patients with and without device-associated healthcare-acquired infectionAdult and paediatric ICUs combinedNo. of deathsNo. of patientsPooled crude mortality, % (95% CI)RR (95% CI)**Crude mortality of patients without DA-HAI1,6166,40825.2 (24.1- 26.3)1.0Crude mortality of patients with CLABSI13335737.3 (32.2- 42.4)1.5 (1.2 -- 1.8)Crude excess mortality of patients with CLABSI13335712.0 (8.1- 16.1)-Crude mortality of patients with CAUTI5515435.7 (28.1- 43.8)1.4 (1.1 -- 1.9)Crude excess mortality of patients with CAUTI5515410.5 (4.0- 17.5)-Crude mortality of patients with VAP25356744.6 (40.4- 48.8)1.8 (1.6 -- 2.0)Crude excess mortality of patients with VAP25356719.4 (16.3- 22.5)-**Neonatal ICUs combinedNo. of deathsNo. of patientsPooled crude mortality, % (95% CI)**Crude mortality of patients without DA-HAI681,9643.5 (2.7- 4.4)1.0Crude mortality of patients with CLABSI105318.9 (9.4- 32.7)5.5 (2.8 -- 10.6)Crude excess mortality of patients with CLABSI105315.4 (6.7- 28.3)-Crude mortality of patients with VAP64314.0 (5.3- 27.9)4.0 (1.8 -- 9.3)Crude excess mortality of patients with VAP64310.5 (2.6- 23.5)-ICU, intensive care units; CI, confidence interval; DA-HAI, device-associated healthcare-acquired infection; CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract infection; RR, relative risk.Table 12**Pooled means of the distribution of the length of stay and crude excess length of stay of intensive care unit patients with and without device-associated healthcare-acquired infectionAdult and paediatric ICUs combinedLOS, total daysNo. of patientsPooled average. LOS, days (95% CI)RR (95% CI)**LOS of patients without DA-HAI50 7166,4087.9 (7.8-7.9)LOS of patients with CLABSI6,92035719.4 (17.5-21.6)2.4 (2.4 -- 2.5)Extra LOS of patients with CLABSI6,92035711.5 (9.7-13.7)LOS of patients with CAUTI2,76915418.0 (15.4-21.2)2.3 (2.2 -- 2.3)Extra LOS of patients with CAUTI2,76915410.1 (7.6-13.3)LOS of patients with VAP9,42656716.6 (15.3-18.1)2.1 (2.0 -- 2.1)Extra LOS of patients with VAP9,4265678.7 (7.5-10.2)**Neonatal ICUs combinedLOS, total daysNo. of patientsPooled average LOS, days**LOS of patients without DA-HAI17,5471,9648.9 (8.5-9.3)LOS of patients with CLABSI1,1695322.1 (16.9-29.5)2.6 (2.3 -- 2.6)Extra LOS of patients with CLABSI1,1695313.1 (16.9-9.5)LOS of patients with VAP1,0814325.1 (18.7-35.7)2.8 (2.6 -- 3.0)Extra LOS of patients with VAP1,0814316.2 (18.7-35.7)LOS, length of stay; DA-HAI, device-associated healthcare-acquired infection; CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract infection.Table 13**Antimicrobial resistance rates in the participating intensive care unitsPathogenic isolated tested, pooled, nResistance, %Pathogenic isolated tested, pooled, nResistance, %Pathogenic isolated tested, pooled, nResistance, %Pathogen, antimicrobial(CLABSI)(CLABSI)(VAP)(VAP)(CAUTI)(CAUTI)***Staphylococcus aureus*Oxacilin47892.7%48283.2%2281.8%*Coagulase- negative staphylococci*Oxacilin51690.3%6981.2%1471.4%*Enterococcus faecalis*Vancomycin805.0%100.0%360.0%*Pseudomonas aeruginosa*Ciprofloxacine20135.3%71940.6%8936.0%Piperacillin or piperacillin-tazobactam27927.6%1,00933.8%12431.5%Amikacin18518.9%67118.3%8116.0%Imipenem or meropenem25137.1%98941.0%12233.6%*Klebsiella pneumoniae*Ceftriaxone or ceftazidime14055.7%16046.3%2850.0%Imipenem or meropenem1896.3%2244.5%731.4%*Acinetobacter baumanii*Imipenem or meropenem46956.1%84462.8%7357.5%*Escherichia Coli*Ceftriaxone or ceftazidime6755.2%7744.2%7851.3%Imipenem or meropenem684.4%1413.5%1322.3%Ciprofloxacine6566.2%11050.0%10433.7%CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract infection.

Table [2](#Tab2){ref-type="table"} shows DA-HAI rates by infection type (CLABSI, CAUTI, VAP) in adult and paediatric ICUs stratified by hospital size and Table [3](#Tab3){ref-type="table"} shows the same information regarding NICUs. In adult and paediatric patients, we found higher rates of CLABSI in the largest hospitals (\>500 beds), however, VAP and CAUTI rates were higher in middle-sized hospitals (201--1000 beds). In NICU patients the rates of CLABSI and VAP were higher in the smallest hospitals (\<200 beds).

Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"} show DA-HAI rates in all the participating ICUs, and in those cases that include NICU patients (Tables [5](#Tab5){ref-type="table"} and [7](#Tab7){ref-type="table"}), the information is divided by weight category. We found that in adult and paediatric patients the highest CLABSI rate was found in the Surgical ICUs, the highest VAP rate in Neurosurgical ICU, and the highest CAUTI rate in Neurologic ICUs. Regarding NICU patients, the highest CLABSI rate was found in patients within the 1000--1500 grams weight category, and the highest VAP rate was found in patients in the 751--1000 grams weight category.

Tables [9](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"} provide data on device use ratios (DURs) for CL, UC and MV and their respective confidence intervals. Central line DUR was higher in the cardiothoracic ICUs, the mechanical ventilator DUR was higher in respiratory ICUs, and the urinary catheter DUR was higher in neurologic ICUs. In the NICU patients the highest DUR for central line and mechanical ventilator were found in \<750 grams birth weight category.

Table [11](#Tab11){ref-type="table"} provides data on crude ICU mortality in patients hospitalized in each type of unit during the surveillance period, with and without DA-HAI, and crude excess mortality of adult and paediatric patients with CLABSI, CAUTI, and VAP, and infants in NICUs with CLABSI or VAP. The DA-HAI associated with a higher mortality was VAP in adult and paediatric patients and CLABSI in NICU patients.

Table [12](#Tab12){ref-type="table"} provides data on crude LOS of patients hospitalized in each ICU during the surveillance period with and without DA-HAI and crude excess LOS of adult and paediatric patients with CLABSI, CAUTI, and VAP and infants in NICUs with CLABSI or VAP. The DA-HAI associated with a longer LOS was CLABSI in adult and paediatric patients and VAP in NICU patients.

Table [13](#Tab13){ref-type="table"} provides data on bacterial resistance of pathogens isolated from patients with DA-HAI in adult and paediatric ICUs and NICUs. We found a high resistance of *Staphylococci aureus* and Coagulase-negative staphylococci to oxacilin in CLABSIs, VAP and CAUTIs.

Tables [14](#Tab14){ref-type="table"} and [15](#Tab15){ref-type="table"} compare the results of this report from Turkey with the INICC international report for the period 2007--2012 and with NHSN report of 2011 \[[@CR5],[@CR10]\]. Overall, we found higher DA-HAI rates in this study than in INICC and NHSN data, as shown in Table [14](#Tab14){ref-type="table"}. DUR was higher in most cases as well, but the central line DUR was lower in paediatric ICUs and NICUs compared to NHSN. Table [15](#Tab15){ref-type="table"} compares the antimicrobial resistance rates of this report from Turkey with the INICC international report for the period 2007--2012 and with NHSN report of 2010--2012. In most cases, we found higher resistance rates than those found in the NHSN report.Table 14**Benchmarking of device-associated healthcare-acquired infection rates in this report against the report of the International Nosocomial Infection Control Consortium (2007--20012) and the report of the US National Healthcare Safety Network Data (2011)This reportINICC report (2007--2012) \[** [@CR10] **\]U.S. NHSN report (2011) \[** [@CR5] **\]Medical surgical ICU**CL, DUR0.65 (0.65 -- 0.65)0.54 (0.54 -- 0.54)0.35 (0.35 -- 0.35)CLABSI rate8.5 (8.0 -- 9.1)4.9 (4.8 -- 5.1)0.9 (0.8 - 0.9)MV, DUR0.54 (0.54 -- 0.54)0.36 (0.36 -- 0.36)0.24 (0.24 -- 0.24)VAP rate22.3 (21.3 - 23.2)16.5 (16.1 -- 16.8)1.1 (9.8 - 1.2)UC, DUR0.88 (0.88 -- 0.88)0.62 (0.62 -- 0.62)0.54 (0.54 -- 0.54)CAUTI rate7.9 (7.5 - 8.4)5.3 (5.2 -- 5.8)1.2 (1.1 - 1.3)**Paediatric ICU**CL, DUR0.40 (0.40 -- 0.41)0.50 (0.50 -- 0.50)0.47 (0.46 -- 0.47)CLABSI rate9.5 (7.9 -- 11.3)6.1 (5.7 -- 6.5)1.8 (1.6 - 1.9)MV, DUR0.53 (0.53 -- 0.54)0.53 (0.53 -- 0.53)0.40 (0.40 -- 0.40)VAP rate11.7 (10.2 - 13.5)7.9 (7.4 -- 8.4)1.1 (9.0 - 1.2)UC, DUR0.34 (0.34 -- 0.35)0.31 (0.31 -- 0.32)0.23 (0.22 -- 0.23)CAUTI rate6.6 (5.2 - 8.4)5.6 (5.1 -- 6.1)3.1 (2.7 - 3.5)**Neonatal ICU (weight 1501 to 2500 grams)**CL, DUR0.09 (0.09 -- 0.10)0.21 (0.20 -- 0.21)0.18 (0.18 -- 0.19)CLABSI rate7.8 (3.4 -- 15.4)4.8 (3.7 -- 6.1)0.7 (0.6 - 0.9)MV, DUR0.12 (0.11 -- 0.13)0.10 (0.10 -- 0.11)0.07 (0.07 -- 0.07)VAP rate14.4 (8.7 - 22.5)10.7 (8.4 -- 13.4)0.5 (0.2 - 0.9)ICU, intensive care unit; CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract infection; DUR, device use ratio; INICC, International Nosocomial Infection Control Consortium; U.S. NSHN, National Healthcare Safety Network of the United States of America.Table 15**Benchmarking of antimicrobial resistance rates in this report against the report of the International Nosocomial Infection Control Consortium (2007--20012) and the report of the US National Healthcare Safety Network Data (2009--2010)This report resistance %INICC 2007--2012 resistance %NHSN 2009--2010 resistance, %Pathogen, antimicrobial(CLABSI)(CLABSI)(CLABSI)***Staphylococcus aureus*Oxacillin92.7%61.2%54.6%*Enterococcus faecalis*Vancomycin5.0%12.2%9.5%*Pseudomonas aeruginosa*Ciprofloxacine35.3%37.5%30.5%Piperacillin or piperacillin-tazobactam27.6%33.5%17.4%Amikacin18.9%42.8%10.0%Imipenem or meropenem37.1%42.4%26.1%*Klebsiella pneumoniae*Ceftriaxone or ceftazidime55.7%71.2%28.8%Imipenem or meropenem6.3%19.6%12.8%*Acinetobacter baumanii*Imipenem or meropenem56.1%66.3%62.6%*Escherichia Coli*Ceftriaxone or ceftazidime55.2%65.9%19.0%Imipenem or meropenem4.4%8.5%1.9%Ciprofloxacine66.2%69.3%41.8%CLABSI, central line-associated bloodstream infection.

Discussion {#Sec9}
==========

Within the scientific literature addressing the burden of DA-HAIs in Turkey's ICUs, in a recent study it was shown that the DA-HAI rates found in their setting were higher than the rates reported by the U.S. NHSN and INICC \[[@CR11]\]. The CLABSI rate of our study was similar to the rate found in another study conducted in Turkey showing 11.8 CLABSIs per 1000 CL days \[[@CR11]\]. Likewise, our CAUTI rate was similar to the findings of another study from ICUs in Turkey, showing 8.3 CAUTIs per 1000 UC days \[[@CR12]\]. The VAP rate in our study was 21.4 per 1000 MV-days in adult and paediatric ICUs. Similarly, in 2008, Erdem et al. found a rate of 22.6 VAPs per 1000 MV-days \[[@CR13]\], and Leblebicioglu et al. found a global VAP rate of 26.5 VAPs per 1000 MV-days in a multi-site study carried out in 12 hospitals in 2007 \[[@CR12]\].

In our Turkish ICUs, DA-HAI rates and pooled DU ratios were higher than the Global INICC Report and U.S. NHSN's data \[[@CR5],[@CR6]\]. Likewise, the antimicrobial resistance rates found in our ICUs were higher than U.S. NHSN \[[@CR4]\] and INICC \[[@CR6]\] report rates for *Staphyloccocus aureus* as resistant to oxacillin, and for *Escherichia Coli* as resistant for imipenem. The resistance of *Escherichia Coli* to ciprofloxacin also higher than than U.S. NHSN \[[@CR4]\], but similar to INICC report. \[[@CR6]\] On the other hand, the resistance rates for *Pseudomonas aeruginosa* were higher in this study than U.S. NHSN report \[[@CR4]\], but lower than the INICC reported resistance rates \[[@CR6]\], as resistant to ciprofloxacin, piperacillin-tazobactam, amikacin and imipenem or meropenem; for *Escherichia Coli* as resistant to ceftriaxone and ceftazidime; and for *Klebsiella pneumonia* as resistant to ceftriaxone or ceftazidime. By contrast, the resistance rates for *Klebsiella pneumonia* and *Acinetobacter baumanii* as resistant to imipenem and meropenem, and *Enterococcus faecalis* as resistant to vancomycin, were lower in this study than in INICC and U.S. NHSN reports \[[@CR4],[@CR6]\].

These high DA-HAI rates may reflect the typical ICU situation in hospitals in Turkey \[[@CR14]\], and several reasons have been exposed to explain this fact \[[@CR11],[@CR15]\]. Among the primary plausible causes, it can be mentioned that, in Turkey there are still no legally enforceable rules or regulations concerning the implementation of infection control programs, such as national infection control guidelines; yet, in the few cases in which there is a legal framework, adherence to the bundles is most irregular and hospital accreditation is not mandatory \[[@CR16]\]. This situation is further emphasized by the fact that administrative and financial support is insufficient to fund infection control programmes, and invariably results in extremely low nurse-to-patient staffing ratios---which have proved to be highly connected to high DA-HAI rates in ICUs---, hospital over-crowding, lack of medical supplies, out-dated medical supplies and in an insufficient number of experienced nurses or trained healthcare workers \[[@CR14]\].

In order to reduce the hospitalized patients' risk of infection, DA-HAI surveillance is primary and essential, because it effectively describes and addresses the importance and characteristics of the threatening situation created by DA-HAIs. This must be followed by the implementation of practices aimed at DA-HAI prevention and control. Additionally, participation in INICC has played a fundamental role, not only in increasing the awareness of DA-HAI risks in the ICU, but also providing an exemplary basis for the institution of infection control practices. Finally, it is of utmost importance to restrict the administration of anti-infective in order to effectively control of antibiotic resistance.

The INICC programme is focused on surveillance of DA-HAIs in the ICU and surveillance of SSIs hospital wide; that is, healthcare settings (ICUs) and procedures (Surgical Procedures) with the highest healthcare-acquired rates, in which patients' safety is most seriously threatened, due to their critical condition and exposure to invasive devices and surgical procedures \[[@CR16]\]. Through the last 12 years, INICC has undertaken a global effort in America, Asia, Africa, Middle East, and Europe to respond to the burden of DA-HAIs, and has achieved extremely successful results, by increasing HH compliance, improving compliance with other infection control bundles and interventions as described in several INICC publications, and consequently reducing the rates of DA-HAI and mortality \[[@CR6],[@CR17]-[@CR21]\].

To compare a hospital\'s DA-HAI rates with the rates identified in this report, it is required that the hospital concerned start by collecting their data by applying the methods and methodology described for U.S. NHSN and INICC, and then calculate infection rates and DU ratios for the DA-HAI Module.

The particular and primary application of these data is to serve as a guide for the implementation of prevention strategies and other quality improvement efforts locally for the reduction of DA-HAI rates to the minimum possible level.

Study limitations {#Sec10}
-----------------

The findings in this report are subject to at least two limitations. First, we did not consider the difference in time periods for the different data sources in the comparisons made with INICC and U.S. NHSN. Second, it is unfortunate that the study did not include data on possible changes in DA-HAIs in Turkey throughout the study period.

Conclusions {#Sec11}
===========

In conclusion, the data presented in this report fortify the fact that DA-HAIs in Turkey pose a grave and many times concealed risk to patient safety, as compared to the developed world. It is INICC's main goal to enhance infection control practices, by facilitating elemental, feasible and inexpensive tools and resources to tackle this problem effectively and systematically, leading to greater and stricter adherence to infection control programs and guidelines, and to the correlated reduction in DA-HAI and its adverse effects, in the hospitals participating in INICC, as well as at any other healthcare facility worldwide.
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